Glyxambi (empagliflozin/linagliptin; Boehringer Ingelheim and Eli Lilly) tablets are now available as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments.
Glyxambi is the first approved drug to combine a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion. Linagliptin is a DPP-4 inhibitor that increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation.
Glyxambi is available in 10-mg/5-mg and 25-mg/5-mg strength tablets in 30-, 90- and 1000-count bottles.
For more information call (800) 542-6257 or visit Glyxambi.com.
This article originally appeared on MPR